JP2003525903A - コリンエステラーゼ阻害剤の新規使用法 - Google Patents
コリンエステラーゼ阻害剤の新規使用法Info
- Publication number
- JP2003525903A JP2003525903A JP2001564766A JP2001564766A JP2003525903A JP 2003525903 A JP2003525903 A JP 2003525903A JP 2001564766 A JP2001564766 A JP 2001564766A JP 2001564766 A JP2001564766 A JP 2001564766A JP 2003525903 A JP2003525903 A JP 2003525903A
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- unsubstituted
- indanone
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 89
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 206010012289 Dementia Diseases 0.000 claims abstract description 56
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims abstract description 20
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Natural products O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960003135 donepezil hydrochloride Drugs 0.000 claims abstract description 13
- 208000019553 vascular disease Diseases 0.000 claims abstract description 10
- -1 (2) pyridyl Chemical group 0.000 claims description 60
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 26
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
- IHMQOBPGHZFGLC-UHFFFAOYSA-N 5,6-dimethoxy-2,3-dihydroinden-1-one Chemical compound C1=C(OC)C(OC)=CC2=C1C(=O)CC2 IHMQOBPGHZFGLC-UHFFFAOYSA-N 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Chemical group 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000005412 pyrazyl group Chemical group 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000005493 quinolyl group Chemical group 0.000 claims description 6
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 6
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 claims description 5
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- VCQUDPHXRPHTFN-UHFFFAOYSA-N 1-prop-1-enylpiperidine Chemical compound CC=CN1CCCCC1 VCQUDPHXRPHTFN-UHFFFAOYSA-N 0.000 claims description 2
- VTDIWMPYBAVEDY-UHFFFAOYSA-N 1-propylpiperidine Chemical compound CCCN1CCCCC1 VTDIWMPYBAVEDY-UHFFFAOYSA-N 0.000 claims description 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims description 2
- GSAHFRQIQURXHP-UHFFFAOYSA-N 5,6-diethoxy-2,3-dihydroinden-1-one Chemical compound C1=C(OCC)C(OCC)=CC2=C1C(=O)CC2 GSAHFRQIQURXHP-UHFFFAOYSA-N 0.000 claims description 2
- QOPRWBRNMPANKN-UHFFFAOYSA-N 5-methoxy-2,3-dihydroinden-1-one Chemical compound COC1=CC=C2C(=O)CCC2=C1 QOPRWBRNMPANKN-UHFFFAOYSA-N 0.000 claims description 2
- TWEJJOTUOVZLSQ-UHFFFAOYSA-N 6-methoxy-5-propan-2-yloxy-2,3-dihydroinden-1-one Chemical compound C(C)(C)OC=1C=C2CCC(C2=CC=1OC)=O TWEJJOTUOVZLSQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229960003530 donepezil Drugs 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 abstract description 63
- 229940122041 Cholinesterase inhibitor Drugs 0.000 abstract description 54
- 208000028698 Cognitive impairment Diseases 0.000 abstract description 46
- 201000000980 schizophrenia Diseases 0.000 abstract description 17
- 206010012218 Delirium Diseases 0.000 abstract description 15
- 208000023105 Huntington disease Diseases 0.000 abstract description 11
- 206010026749 Mania Diseases 0.000 abstract description 11
- 208000020016 psychiatric disease Diseases 0.000 abstract description 11
- 241000208125 Nicotiana Species 0.000 abstract description 10
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract description 10
- 206010027175 memory impairment Diseases 0.000 abstract description 10
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 9
- 230000003920 cognitive function Effects 0.000 abstract description 9
- 206010028417 myasthenia gravis Diseases 0.000 abstract description 9
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract description 8
- 206010015037 epilepsy Diseases 0.000 abstract description 8
- 208000030507 AIDS Diseases 0.000 abstract description 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract description 7
- 206010003805 Autism Diseases 0.000 abstract description 7
- 208000020706 Autistic disease Diseases 0.000 abstract description 7
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract description 7
- 208000018737 Parkinson disease Diseases 0.000 abstract description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract description 7
- 206010048010 Withdrawal syndrome Diseases 0.000 abstract description 7
- 229940039856 aricept Drugs 0.000 abstract description 7
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract description 7
- 208000029028 brain injury Diseases 0.000 abstract description 7
- 230000004064 dysfunction Effects 0.000 abstract description 7
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 7
- 201000002859 sleep apnea Diseases 0.000 abstract description 7
- 230000009529 traumatic brain injury Effects 0.000 abstract description 7
- 208000003174 Brain Neoplasms Diseases 0.000 abstract description 6
- 201000010374 Down Syndrome Diseases 0.000 abstract description 6
- 208000006289 Rett Syndrome Diseases 0.000 abstract description 6
- 208000000323 Tourette Syndrome Diseases 0.000 abstract description 6
- 208000016620 Tourette disease Diseases 0.000 abstract description 6
- 238000002512 chemotherapy Methods 0.000 abstract description 6
- 210000004351 coronary vessel Anatomy 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 230000000926 neurological effect Effects 0.000 abstract description 6
- 201000002212 progressive supranuclear palsy Diseases 0.000 abstract description 6
- 208000021642 Muscular disease Diseases 0.000 abstract description 5
- 201000009623 Myopathy Diseases 0.000 abstract description 5
- 206010013932 dyslexia Diseases 0.000 abstract description 5
- 208000027061 mild cognitive impairment Diseases 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 230000006996 mental state Effects 0.000 abstract description 4
- 210000004558 lewy body Anatomy 0.000 abstract description 3
- 238000001356 surgical procedure Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 description 36
- 208000024891 symptom Diseases 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 206010002942 Apathy Diseases 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 208000004547 Hallucinations Diseases 0.000 description 6
- 206010022998 Irritability Diseases 0.000 description 6
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 206010038743 Restlessness Diseases 0.000 description 5
- 206010044565 Tremor Diseases 0.000 description 5
- 201000004810 Vascular dementia Diseases 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 208000004209 confusion Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 206010013395 disorientation Diseases 0.000 description 5
- 208000024714 major depressive disease Diseases 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 229960002715 nicotine Drugs 0.000 description 5
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 4
- 208000014644 Brain disease Diseases 0.000 description 4
- 206010012239 Delusion Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 208000009829 Lewy Body Disease Diseases 0.000 description 4
- 201000002832 Lewy body dementia Diseases 0.000 description 4
- 208000001431 Psychomotor Agitation Diseases 0.000 description 4
- 231100000868 delusion Toxicity 0.000 description 4
- 208000024732 dysthymic disease Diseases 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 206010019196 Head injury Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 201000006347 Intellectual Disability Diseases 0.000 description 3
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000004442 acylamino group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000007278 cognition impairment Effects 0.000 description 3
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000002635 electroconvulsive therapy Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000008449 language Effects 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 208000027104 Chemotherapy-Related Cognitive Impairment Diseases 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 206010021030 Hypomania Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 208000025069 Juvenile Huntington disease Diseases 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 206010034719 Personality change Diseases 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 2
- 206010040030 Sensory loss Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000006741 behavioral dysfunction Effects 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000000739 chaotic effect Effects 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 150000003950 cyclic amides Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 208000017004 dementia pugilistica Diseases 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000037315 hyperhidrosis Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 125000003884 phenylalkyl group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000003997 social interaction Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ILFIRBGRMCGNOO-UHFFFAOYSA-N 1,1-bis($l^{1}-oxidanyl)ethene Chemical group [O]C([O])=C ILFIRBGRMCGNOO-UHFFFAOYSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- IJCWFKHKIKRUAR-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1,2-benzodiazepin-3-one Chemical compound N1NC(=O)CCC2=CC=CC=C21 IJCWFKHKIKRUAR-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- VXIUQBQARXJTPN-UHFFFAOYSA-N 2,2-dimethoxy-3h-inden-1-one Chemical compound C1=CC=C2C(=O)C(OC)(OC)CC2=C1 VXIUQBQARXJTPN-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NTNKZGHUNBWBBV-UHFFFAOYSA-N 3,4,4a,5-tetrahydro-2h-isoquinolin-1-one Chemical compound C1C=CC=C2C(=O)NCCC21 NTNKZGHUNBWBBV-UHFFFAOYSA-N 0.000 description 1
- IWGYHCPYYVQFCK-UHFFFAOYSA-N 3,4,5,6,6a,7-hexahydro-1h-1-benzazocin-2-one Chemical compound N1C(=O)CCCCC2CC=CC=C21 IWGYHCPYYVQFCK-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000009810 Catatonic Schizophrenia Diseases 0.000 description 1
- 208000003417 Central Sleep Apnea Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010009696 Clumsiness Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 206010059138 Glossoptosis Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020575 Hyperammonaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000030979 Language Development disease Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000032443 Masked facies Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010061285 Mental disorder due to a general medical condition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000036755 Schizophrenia simple Diseases 0.000 description 1
- 208000036754 Schizophrenia, catatonic type Diseases 0.000 description 1
- 208000036750 Schizophrenia, residual type Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 206010048327 Supranuclear palsy Diseases 0.000 description 1
- 206010068932 Terminal insomnia Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 206010045178 Tunnel vision Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010067775 Upper airway obstruction Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 201000004988 autoimmune vasculitis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000013677 cerebrovascular dementia Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001263 extrapyramidal tract Anatomy 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 201000007350 frontal lobe neoplasm Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 125000006257 n-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])OC(*)=O 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical class C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18674400P | 2000-03-03 | 2000-03-03 | |
| US60/186,744 | 2000-03-03 | ||
| US19761000P | 2000-04-18 | 2000-04-18 | |
| US60/197,610 | 2000-04-18 | ||
| US22078300P | 2000-07-25 | 2000-07-25 | |
| US60/220,783 | 2000-07-25 | ||
| US25922601P | 2001-01-03 | 2001-01-03 | |
| US60/259,226 | 2001-01-03 | ||
| PCT/US2001/007027 WO2001066114A1 (en) | 2000-03-03 | 2001-03-05 | Novel methods using cholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2003525903A true JP2003525903A (ja) | 2003-09-02 |
Family
ID=27497683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001564766A Pending JP2003525903A (ja) | 2000-03-03 | 2001-03-05 | コリンエステラーゼ阻害剤の新規使用法 |
Country Status (11)
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005027968A1 (ja) * | 2003-09-19 | 2005-03-31 | Eisai Co., Ltd. | ダウン症候群治療剤 |
| JP2007519738A (ja) * | 2004-01-30 | 2007-07-19 | アクソニクス，インコーポレイテッド | 糖尿病の合併症の治療方法 |
| JP2007519733A (ja) * | 2004-01-26 | 2007-07-19 | コーテックス ファーマシューティカルズ インコーポレーティッド | アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法 |
| JP2016531146A (ja) * | 2013-09-10 | 2016-10-06 | アーリーン ファーマシューティカルズ エルエルシー | 多発性硬化症を治療するためのレチノイン酸関連核内オーファン受容体拮抗剤である置換された２，３−ジヒドロ−１ｈ−インデン−１−オン |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| PT1311272E (pt) * | 2000-03-03 | 2007-02-28 | Eisai R&D Man Co Ltd | Novos métodos utilizando inibidores de colinesterase |
| US20030153598A1 (en) * | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
| AU2002245692A1 (en) * | 2001-03-15 | 2002-10-03 | David Pharmaceuticals | Methods for restoring cognitive function following systemic stress |
| WO2003020289A1 (en) * | 2001-08-30 | 2003-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
| WO2003032914A2 (en) * | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
| JPWO2003061658A1 (ja) * | 2002-01-22 | 2005-05-19 | エーザイ株式会社 | インダノン誘導体を含有するシグマ受容体結合剤 |
| US20030162770A1 (en) * | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20070053976A1 (en) * | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
| US20060129385A1 (en) * | 2002-07-22 | 2006-06-15 | Heller James H | Cholinergic therapy for individuals with learning disabilities |
| AU2003287433A1 (en) * | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
| CA2516618A1 (en) * | 2003-02-27 | 2004-09-10 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Pharmaceutical composition for treatment of drug dependence |
| US7723349B2 (en) | 2003-04-24 | 2010-05-25 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| IL155666A (en) * | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Insomnia treatment |
| US9119846B2 (en) * | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
| CA2567746A1 (en) * | 2003-05-23 | 2005-01-06 | Cognition Pharmaceuticals Llc | Methods for treating cognitive impairment and improving cognition |
| JP4137159B2 (ja) | 2003-06-17 | 2008-08-20 | ファイザー・インク | セロトニン及びノルアドレナリン再取り込み阻害薬としてのｎ−ピロリジン−３−イル−アミド誘導体 |
| US20050232990A1 (en) * | 2003-12-31 | 2005-10-20 | Garth Boehm | Donepezil formulations |
| EP1743036A4 (en) * | 2004-01-22 | 2008-07-02 | Genaissance Pharmaceuticals | APOE GENERAL MARKERS RELATED TO ALZHEIMER IN THE FIRST EARLY PERIOD |
| CA2559285A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| JP2007538004A (ja) * | 2004-03-18 | 2007-12-27 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | シヌクレイノパチーを治療する方法 |
| CA2559282A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| TW200533371A (en) * | 2004-04-15 | 2005-10-16 | Dainippon Pharmaceutical Co | Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative |
| US20060135507A1 (en) * | 2004-08-13 | 2006-06-22 | Osamu Yokoyama | Therapeutic agent for overactive bladder involved in aging |
| US20060079558A1 (en) * | 2004-09-27 | 2006-04-13 | Bridge Pharma. Inc. | R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics |
| WO2006036936A2 (en) * | 2004-09-27 | 2006-04-06 | Bridge Pharma, Inc. | The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents |
| RS51822B (en) * | 2005-04-04 | 2012-02-29 | Eisai R. &D. Management Co. Ltd. | DIHYDROPYRIDINE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND Dementia |
| GB0605544D0 (en) * | 2006-03-20 | 2006-04-26 | Univ Nottingham | Genetic Markers For Alzheimer Disease |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| WO2007143600A2 (en) * | 2006-06-05 | 2007-12-13 | Incyte Corporation | Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases |
| CA2655809C (en) * | 2006-07-21 | 2013-10-01 | Bridge Pharma, Inc. | Dermal anesthetic compounds |
| US8012994B1 (en) | 2006-09-22 | 2011-09-06 | Sevastyanov Victor V | Method for the treatment of sensorineural hearing loss with donepezil hydrochloride (ARICEPT®) |
| KR101408454B1 (ko) * | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | 도네페질 함유 접착 제제의 착색을 억제하는 방법 및 도네페질의 친척 물질의 생성량을 감소시키는 방법 |
| US20080131491A1 (en) * | 2006-12-01 | 2008-06-05 | Akinori Hanatani | Percutaneously absorbable preparation |
| EP2131828A2 (en) * | 2007-03-05 | 2009-12-16 | Eisai R&D Management Co., Ltd. | Ampa and nmda receptor antagonists for neurodegenerative diseases |
| JP2010524844A (ja) * | 2007-04-26 | 2010-07-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 認知症のためのシンナミド化合物 |
| JP2010526825A (ja) * | 2007-05-10 | 2010-08-05 | エーエムアール テクノロジー インコーポレイテッド | アリール置換およびヘテロアリール置換テトラヒドロベンゾ−１，４−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
| JP2011502966A (ja) * | 2007-10-31 | 2011-01-27 | アルセレス ファーマシューティカルズ， インコーポレイテッド | ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法 |
| US20090156561A1 (en) * | 2007-12-13 | 2009-06-18 | Seed John C | Use of Cholinesterase Inhibitors In Smoking Cessation |
| US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| US20110034565A1 (en) | 2008-04-18 | 2011-02-10 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| US20090291127A1 (en) * | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| WO2009145177A1 (ja) * | 2008-05-30 | 2009-12-03 | 日東電工株式会社 | ドネペジル含有貼付製剤およびその包装体 |
| CN102046171B (zh) * | 2008-05-30 | 2013-06-19 | 日东电工株式会社 | 经皮吸收制剂 |
| BRPI0917862A2 (pt) * | 2008-09-30 | 2015-11-24 | Teikoku Pharma Usa Inc | composições transdérmicas de donepezil com distribuição prolongada e métodos para usar as mesmas |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| BRPI0920927A2 (pt) * | 2008-11-13 | 2019-09-24 | Link Medicine Corp | derivados de azaquinolinona e usos dos mesmos |
| JP2012523437A (ja) * | 2009-04-13 | 2012-10-04 | セラヴァンス， インコーポレーテッド | 認知障害の治療のための５−ｈｔ４受容体アゴニスト化合物 |
| US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| CA2789014C (en) | 2010-02-09 | 2019-01-15 | Michela Gallagher | Methods and compositions for improving cognitive function |
| EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
| WO2011127235A1 (en) | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
| GR1007368B (el) | 2010-05-27 | 2011-08-02 | Alapis Α.Β.Ε.Ε., | Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας |
| WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
| US8980924B2 (en) | 2010-11-24 | 2015-03-17 | The Trustees Of Columbia University In The City Of New York | Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease |
| US20120225922A1 (en) | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
| US9265738B2 (en) | 2012-01-20 | 2016-02-23 | The Board Of Trustees Of The Leland Stanford Junior University | Small molecule CMKLR1 antagonists in demyelinating disease |
| US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
| US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
| ES2700541T3 (es) | 2013-03-14 | 2019-02-18 | Univ Columbia | Octahidrociclopentapirroles, su preparación y uso |
| US10273243B2 (en) | 2013-03-14 | 2019-04-30 | The Trustees Of Columbia University In The City Of New York | 4-phenylpiperidines, their preparation and use |
| CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2015168286A1 (en) | 2014-04-30 | 2015-11-05 | The Trustees Of Columbia University In The City Of New York | Substituted 4-phenylpiperidines, their preparaiton and use |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| WO2016126926A1 (en) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
| EP3253759A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| US9932351B2 (en) | 2015-02-05 | 2018-04-03 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| EP3334425B1 (en) * | 2015-08-14 | 2020-12-16 | QR Pharma | Methods of treatment or prevention of acute brain or nerve injuries |
| CA3083015A1 (en) | 2017-05-24 | 2018-11-28 | Qr Pharma, Inc. | Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans |
| AU2018360730A1 (en) | 2017-10-30 | 2020-05-21 | Montreal Heart Institute | Methods of treating elevated plasma cholesterol |
| CA3146794A1 (en) * | 2019-07-16 | 2021-01-21 | Rush University Medical Center | Use of a benzoate containing composition to treat neurodegenerative disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02169569A (ja) * | 1988-12-22 | 1990-06-29 | Eisai Co Ltd | 環状アミン誘導体を含有する医薬 |
| JPH07252216A (ja) * | 1987-06-22 | 1995-10-03 | Eisai Co Ltd | 環状アミン誘導体 |
| WO1998039000A1 (en) * | 1997-03-03 | 1998-09-11 | Eisai Co., Ltd. | Use of cholinesterase inhibitors to treat disorders of attention |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL74497A (en) * | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| US4826843A (en) * | 1985-07-08 | 1989-05-02 | Bristol-Myers | Cerebral function enhancing diazinylpiperidine derivatives |
| JP3075566B2 (ja) | 1990-05-15 | 2000-08-14 | エーザイ株式会社 | 光学活性インダノン誘導体 |
| JP2965675B2 (ja) | 1990-11-21 | 1999-10-18 | エーザイ株式会社 | （―）―１―ベンジル―４―〔（５，６―ジメトキシ―１―インダノン）―２―イル〕メチルピペリジンの製造方法 |
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| AU665207B2 (en) * | 1991-07-29 | 1995-12-21 | Warner-Lambert Company | Quinazoline derivatives as acetylcholinesterase inhibitors |
| SE9103752D0 (sv) * | 1991-12-18 | 1991-12-18 | Astra Ab | New compounds |
| TW513409B (en) | 1996-06-07 | 2002-12-11 | Eisai Co Ltd | Polymorphs of donepezil hydrochloride |
| CA2252806C (en) | 1996-06-07 | 2005-11-22 | Eisai Co., Ltd. | Polymorphs of donepezil hydrochloride and process for production |
| AU1153097A (en) | 1996-06-07 | 1998-01-05 | Eisai Co. Ltd. | Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production |
| WO1998007431A1 (en) * | 1996-08-22 | 1998-02-26 | New York University | Cholinesterase inhibitors for treatment of parkinson's disease |
| AU9454098A (en) * | 1997-09-24 | 1999-04-12 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
| ATE260896T1 (de) | 1997-12-05 | 2004-03-15 | Eisai Co Ltd | Donepezil polykristalle und verfharen zu ihrer herstellung |
| DE69924467T2 (de) | 1998-01-16 | 2006-02-16 | Eisai Co., Ltd. | Verfahren zur herstellung von donepezilderivaten |
| US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
| KR100801236B1 (ko) | 1998-08-28 | 2008-02-11 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고미 등을 경감한 의약조성물 |
| IT1304904B1 (it) | 1998-09-11 | 2001-04-05 | Eisai Co Ltd | Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche |
| WO2000059544A1 (fr) | 1999-03-31 | 2000-10-12 | Eisai Co., Ltd. | Compositions stabilisees contenant des medicaments nootropes |
| PT1311272E (pt) * | 2000-03-03 | 2007-02-28 | Eisai R&D Man Co Ltd | Novos métodos utilizando inibidores de colinesterase |
| US20030153598A1 (en) * | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
| US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| US20030144255A1 (en) | 2000-03-06 | 2003-07-31 | Bain Allen I | Compositions for prevention and treatment of dementia |
| US20010036949A1 (en) | 2000-05-09 | 2001-11-01 | Coe Jotham Wadsworth | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| WO2003024456A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating and preventing migraines |
| WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
| WO2003032914A2 (en) | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
| WO2003092606A2 (en) | 2002-05-01 | 2003-11-13 | Eisai Co., Ltd. | Cholinesterase inhibitors to prevent injuries caused by chemicals |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| AU2003287433A1 (en) * | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
-
2001
- 2001-03-05 PT PT01922272T patent/PT1311272E/pt unknown
- 2001-03-05 WO PCT/US2001/007027 patent/WO2001066114A1/en active IP Right Grant
- 2001-03-05 EP EP09011085A patent/EP2140868A1/en not_active Withdrawn
- 2001-03-05 ES ES01922272T patent/ES2275670T3/es not_active Expired - Lifetime
- 2001-03-05 AT AT01922272T patent/ATE345803T1/de active
- 2001-03-05 AU AU2001249091A patent/AU2001249091A1/en not_active Abandoned
- 2001-03-05 EP EP01922272A patent/EP1311272B1/en not_active Expired - Lifetime
- 2001-03-05 DK DK01922272T patent/DK1311272T3/da active
- 2001-03-05 EP EP09011084A patent/EP2133078A1/en not_active Withdrawn
- 2001-03-05 JP JP2001564766A patent/JP2003525903A/ja active Pending
- 2001-03-05 EP EP09011051A patent/EP2138177A1/en not_active Withdrawn
- 2001-03-05 DE DE60124730T patent/DE60124730T2/de not_active Expired - Lifetime
- 2001-03-05 EP EP09011050A patent/EP2130538A1/en not_active Withdrawn
- 2001-07-06 US US09/899,028 patent/US20020035128A1/en not_active Abandoned
- 2001-09-04 US US09/947,087 patent/US6482838B2/en not_active Expired - Fee Related
- 2001-09-04 US US09/947,086 patent/US6458807B1/en not_active Expired - Lifetime
-
2002
- 2002-01-25 US US10/054,931 patent/US6576646B1/en not_active Expired - Fee Related
- 2002-09-03 US US10/232,406 patent/US6689795B2/en not_active Expired - Fee Related
-
2003
- 2003-12-11 US US10/732,349 patent/US7563808B2/en not_active Expired - Fee Related
-
2005
- 2005-07-15 US US11/181,855 patent/US20050250812A1/en not_active Abandoned
-
2007
- 2007-01-29 CY CY20071100121T patent/CY1107997T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07252216A (ja) * | 1987-06-22 | 1995-10-03 | Eisai Co Ltd | 環状アミン誘導体 |
| JPH02169569A (ja) * | 1988-12-22 | 1990-06-29 | Eisai Co Ltd | 環状アミン誘導体を含有する医薬 |
| WO1998039000A1 (en) * | 1997-03-03 | 1998-09-11 | Eisai Co., Ltd. | Use of cholinesterase inhibitors to treat disorders of attention |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005027968A1 (ja) * | 2003-09-19 | 2005-03-31 | Eisai Co., Ltd. | ダウン症候群治療剤 |
| JP2007519733A (ja) * | 2004-01-26 | 2007-07-19 | コーテックス ファーマシューティカルズ インコーポレーティッド | アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法 |
| JP2007519738A (ja) * | 2004-01-30 | 2007-07-19 | アクソニクス，インコーポレイテッド | 糖尿病の合併症の治療方法 |
| JP2016531146A (ja) * | 2013-09-10 | 2016-10-06 | アーリーン ファーマシューティカルズ エルエルシー | 多発性硬化症を治療するためのレチノイン酸関連核内オーファン受容体拮抗剤である置換された２，３−ジヒドロ−１ｈ−インデン−１−オン |
| US10172866B2 (en) | 2013-09-10 | 2019-01-08 | Arrien Pharmaceuticals Llc | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis |
| US10682358B2 (en) | 2013-09-10 | 2020-06-16 | Arrien Pharmaceuticals Llc | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis |
Also Published As
| Publication number | Publication date |
|---|---|
| US20020035129A1 (en) | 2002-03-21 |
| EP1311272B1 (en) | 2006-11-22 |
| US20020035128A1 (en) | 2002-03-21 |
| WO2001066114A1 (en) | 2001-09-13 |
| US6458807B1 (en) | 2002-10-01 |
| CY1107997T1 (el) | 2013-09-04 |
| AU2001249091A1 (en) | 2001-09-17 |
| EP1311272A4 (en) | 2003-05-21 |
| DK1311272T3 (da) | 2007-02-26 |
| PT1311272E (pt) | 2007-02-28 |
| US20040122051A1 (en) | 2004-06-24 |
| US6576646B1 (en) | 2003-06-10 |
| ATE345803T1 (de) | 2006-12-15 |
| US20050250812A1 (en) | 2005-11-10 |
| EP1311272A1 (en) | 2003-05-21 |
| EP2138177A1 (en) | 2009-12-30 |
| DE60124730D1 (de) | 2007-01-04 |
| EP2140868A1 (en) | 2010-01-06 |
| EP2133078A1 (en) | 2009-12-16 |
| US7563808B2 (en) | 2009-07-21 |
| DE60124730T2 (de) | 2007-10-04 |
| US20020040038A1 (en) | 2002-04-04 |
| US6689795B2 (en) | 2004-02-10 |
| US6482838B2 (en) | 2002-11-19 |
| ES2275670T3 (es) | 2007-06-16 |
| EP2130538A1 (en) | 2009-12-09 |
| US20030040532A1 (en) | 2003-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003525903A (ja) | コリンエステラーゼ阻害剤の新規使用法 | |
| US20060183776A9 (en) | Liquid dosage formulations of donepezil | |
| KR20230003503A (ko) | 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민 | |
| US20080242682A1 (en) | Preventive or Therapeutic Agent for Sleep Disorder | |
| US7449490B2 (en) | Pharmaceutically active compounds and methods of use | |
| EP2477624B1 (en) | Compounds for use in the treatment of seizure disorders | |
| KR20120103557A (ko) | 파킨슨씨병 치료용 조성물 및 치료방법 | |
| US5434177A (en) | Imidazoles for the treatment of age-related cognitive disorders and alzheimer | |
| AU2002303191A1 (en) | Pharmaceutically active compounds and methods of use | |
| JP2007186434A (ja) | 医薬組成物 | |
| CN101001627A (zh) | 用于治疗与缺血性卒中相关的脑血管疾病的吡唑啉酮化合物 | |
| EP1764101A1 (en) | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments | |
| EP1685849B1 (en) | Pde 4 inhibitors for the treatment of interstitial cystitis | |
| KR100735513B1 (ko) | Ｒ(+)-α-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 수면 장애 치료용 약제학적 조성물 | |
| JPH0233689B2 (US06576646-20030610-C00002.png) | ||
| EP1666066A1 (en) | Remedy for down syndrome | |
| US20100227844A1 (en) | Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease | |
| WO1998026778A1 (fr) | Medicaments pour traiter/prevenir les mouvements anormaux qui accompagnent les troubles du systeme nerveux extrapyramidal | |
| JP2007512269A (ja) | 統合失調症性精神病の処置のためのデオキシペガニンの使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080304 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20090227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090227 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090409 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090409 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090409 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110426 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111025 |